Why Ono’s Phase 2 MSA data may matter beyond one World Parkinson Congress poster
Ono’s ONO-2808 data hints at disease modification in MSA. See why Phase 3 may decide whether the signal becomes a breakthrough.
Can Ono Pharmaceutical bring clearer treatment sequencing to advanced GIST in Japan?
Ono Pharmaceutical has filed ripretinib in Japan for advanced GIST. Read why the move could reshape late-line treatment access and sequencing.
Ono Pharmaceutical strengthens early-stage pipeline with Congruence platform deal
Ono Pharmaceutical expands its Congruence alliance into neurology and immunology. Explore what this means for AI-driven drug discovery and pipeline risk.
Why Deciphera Pharmaceuticals’ tirabrutinib NDA matters for the future of CNS lymphoma therapy
FDA accepts tirabrutinib NDA for relapsed or refractory PCNSL. Find out what this means for CNS lymphoma treatment and regulatory strategy.